Area of research
Cardiology and Cardiovascular Medicine · Internal Medicine
Research interest
Research interests include Atrial Fibrillation Management and Outcomes, Antiplatelet Therapy and Cardiovascular Diseases, Venous Thromboembolism Diagnosis and Management, and Cardiac Imaging and Diagnostics.
Trends in sudden death-attributed mortality across Europe, 2010–2020: a retrospective population-based analysis
Fibrinolytic Therapy for Thromboembolic Diseases
Myocardial ischaemic syndromes: a new nomenclature to harmonize evolving international clinical practice guidelines
Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease
Myocardial Revascularization in Patients With Ischemic Cardiomyopathy: For Whom and How
Cardiovascular Morbidity and Mortality Related to Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis
Additional value of T1 and T2 mapping techniques for early detection of myocardial involvement in scleroderma
Declining trends of premature mortality from ischemic heart disease and regional differences in Italy from 2011 to 2017
Antithrombotic therapy following revascularization for chronic limb-threatening ischaemia: a European survey from the ESC Working Group on Aorta and Peripheral Vascular Diseases
A Prospective Study to Evaluate the Effectiveness of Edoxaban for the Resolution of Left Atrial Thrombosis in Patients with Atrial Fibrillation
Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI)
COVID-19-related cardiac complications from clinical evidences to basic mechanisms: opinion paper of the ESC Working Group on Cellular Biology of the Heart
Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era
Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence
Evaluation of the Age, Biomarkers, and Clinical History–Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials
ESC Working Group on Cellular Biology of the Heart: position paper for Cardiovascular Research: tissue engineering strategies combined with cell therapies for cardiac repair in ischaemic heart disease and heart failure
Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF)
Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation
Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial
Thrombotic and hemorrhagic burden in women: Gender-related issues in the response to antithrombotic therapies
Endothelial Dysfunction, Fibrinolytic Activity, and Coagulation Activity in Patients With Atrial Fibrillation According to Type II Diabetes Mellitus Status
The co‐predictive value of a cardiovascular score for CV outcomes in diabetic patients with no atrial fibrillation
La trombosi atriale e auricolare sinistra nei pazienti con fibrillazione atriale: dalla fisiopatologia al trattamento
Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial
Digoxin and Mortality in Patients With Atrial Fibrillation
Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs
Mechanical prosthetic heart valves: Quality of anticoagulation and thromboembolic risk. The observational multicenter PLECTRUM study
Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy
Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations